性腺毒性治疗后的生育力保存:当前证据、可行性与结局
综述探讨癌症幸存者在性腺毒性治疗后进行生育力保存的证据、可行性与结局。既往性腺毒性治疗不应视为干预的绝对障碍,管理应综合年龄、治疗前后卵巢储备、治疗类型与累积暴露、疾病状态及生育目标。青春后期有可募集卵泡者通常首选卵母细胞或胚胎冷冻,卵巢组织冷冻可选择性考虑。
要点
- 既往性腺毒性治疗不应视为生育力保存的绝对障碍
- 管理需整合年龄、卵巢储备、治疗暴露、疾病状态与生育目标
- 青春后期有可募集卵泡者首选卵母细胞或胚胎冷冻
核心结论
- 既往性腺毒性治疗不应被视为生育力保存干预的绝对障碍,管理应个体化整合多因素决策。
研究设计与样本
- 综述,聚焦性腺毒性治疗后生育力保存的证据、可行性、结局、安全性及新兴恢复技术。
主要发现
- 癌症生存改善使生殖健康成为幸存者照护的重要组成。
- 许多幸存者未在治疗前接受干预、储存的生殖材料不足或后续需额外性腺毒性治疗。
- 指导暴露后生育力保存的证据仍有限且异质。
关键数值与推荐
- 青春后期有可募集卵泡的幸存者通常首选卵母细胞或胚胎冷冻。
- 卵巢组织冷冻可选择性考虑。
- 管理应整合年龄、治疗前后卵巢储备、治疗类型与累积暴露、疾病状态、预期进一步治疗及生育目标。
临床怎么用
- 对既往接受性腺毒性治疗且有生育需求的幸存者,应评估残余生殖潜力并个体化选择保存策略。
- 不应因既往性腺毒性治疗而直接排除生育力保存干预。
- 青春后期有可募集卵泡者可优先考虑卵母细胞或胚胎冷冻,选择性考虑卵巢组织冷冻。
局限性
- 指导暴露后生育力保存的证据仍有限且异质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improved cancer survival has made reproductive health an essential component of survivorship care. Although fertility preservation has traditionally focused on interventions before gonadotoxic therapy, many survivors received no before-treatment intervention, stored insufficient reproductive material, or later require additional gonadotoxic therapy. Evidence guiding fertility preservation after exposure remains limited and heterogeneous. This review examines treatment-induced ovarian injury, assessment of residual reproductive potential, candidate selection and timing, available fertility-preservation strategies, reproductive outcomes, safety, and emerging restorative technologies. Previous gonadotoxic therapy should not be considered an absolute barrier to intervention. Management should instead integrate age, before-treatment and current ovarian reserve, treatment type and cumulative exposure, disease status, anticipated further therapy, and reproductive goals. Oocyte or embryo cryopreservation is generally preferred for postpubertal survivors with recruitable follicles, whereas ovarian tissue cryopreservation may be considered selectively. Because the fertility-preservation field continues to evolve, individualized prediction of residual reproductive potential and the development of safe fertility-restoring strategies are expected to redefine reproductive care for cancer survivors who present after gonadotoxic treatment.
引用
- Angelini E, Oktay KH. Fertility preservation after gonadotoxic treatment: current evidence, feasibility, and outcomes. Fertil Steril. 2026. PMID: 42869369. doi:10.1016/j.fertnstert.2026.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。